ArticleNeuropathology and applied neurobiology2026
Prognostic Markers in Meningioma: Effectiveness of FISH-Assessed CDKN2A/B Homozygous Deletion and Limits of Surrogate p16/MTAP Immunohistochemistry in Predicting Disease-Specific Survival.
Article in Neuropathology and applied neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
aimsHomozygous deletion (HD) of CDKN2A/B represents an adverse prognostic biomarker in meningiomas and a diagnostic criterion for CNS WHO grade 3 assignment. However, fluorescence in situ hybridisation (FISH) thresholds and the role of immunohistochemistry (IHC) surrogates remain uncertain. This study evaluated multiple CDKN2A/B FISH cutoffs and assessed the diagnostic and prognostic performance of MTAP and p16 IHC. METHODS AND
resultsNinety-two meningiomas (CNS WHO grades 1-3) were analysed by FISH evaluating ≥ 10%, ≥ 20% and ≥ 30% CDKN2A/B HD thresholds. CDKN2A/B HD was identified in 18.5%, 6.5% and 4.3% of cases using the respective cutoffs and was significantly associated with shorter disease-specific survival across all thresholds (HD ≥ 10% p = 0.001; HD ≥ 20% p = 0.0001; HD ≥ 30% p = 0.043). Patients with HD ≥ 20% and ≥ 30% experienced universal disease-specific mortality within a median survival time of approximately 2 years. MTAP and p16 IHC were performed in matched areas. MTAP IHC showed high specificity (90%-92%) but limited sensitivity (30%-50%), while p16 IHC displayed variable sensitivity (41%-75%) and lower specificity (63%). Combined MTAP/p16 negativity improved sensitivity (up to 100%) but reduced specificity (57%). Neither MTAP nor p16 loss correlated significantly with survival. Spatially heterogeneous IHC patterns corresponded to regional variability in CDKN2A/B deletion by FISH.
conclusionsCDKN2A/B HD detected by FISH, particularly using thresholds equal or greater than 20%, is strongly associated with poor outcome in meningiomas. MTAP and p16 IHC, alone or combined, lack sufficient accuracy as independent surrogates but may guide tissue selection for molecular testing in heterogeneous tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.